Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy - Supplementary dataset
Hepatocellular carcinoma (HCC) poses a severe threat to human health and economic development.
Despite many attempts at HCC treatment, most are inevitably affected by the genetic instability and
variability of tumor cells. Arsenic trioxide (ATO) has shown to be effective in HCC. However, timeconsuming
challenges, especially the optimal concentration in tumor tissue and bioavailability of ATO,
remain to be overcome for its transition from the bench to the bedside. To bypass these issues,
nanotechnology-based delivery systems have been developed for prevention, diagnosis, monitoring and
treatment in recent years. This article is a systematic overview of the latest contributions and detailed
insights into ATO-loaded nanocarriers, with particular attention paid to strategies for improving the
efficacy of nanocarriers of ATO.